High-dose recombinant factor VIIa therapy in hemophilia patients with inhibitors

Seminars in Hematology

Volumn 43, Issue SUPPL. 1, 2006, Pages

  Kenet, Gili ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN;

BLEEDING; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HEMARTHROSIS; HEMOPHILIA; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; THROMBOELASTOGRAPHY;

BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FACTOR VII; HEMOPHILIA A; HEMORRHAGE; HUMANS; INFANT; INFANT, NEWBORN; RECOMBINANT PROTEINS;

EID: 31444446915     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2005.11.006     Document Type: Conference Paper

References (29)

1. E. Santagostino, M.E. Mancuso, A. Rocino, G. Mancuso, M.G. Mazzucconi, A. Tagliaferri Environmental risk factors for inhibitor development in children with haemophilia A A case-control study Br J Haematol 130 2005 422 427
2. G.C. White 2nd, C.L. Kempton, A. Grimsley, B. Nielsen, H.R. Roberts Cellular immune responses in hemophilia Why do inhibitors develop in some, but not all hemophiliacs? J Thromb Haemost 3 2005 1676 1681
3. J.M. Lusher Inhibitor antibodies to factor VIII and factor IX Management Semin Thromb Hemost 26 2000 179 188
4. E. Erhardtsen Pharmacokinetics of recombinant activated factor VII (rFVIIa) Semin Thromb Hemost 26 2000 385 391
5. A.D. Shapiro, G.S. Gilchrist, W.K. Hoots, H.A. Cooper, D.A. Gastineau Prospective, randomized trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery Thromb Haemost 80 1998 773 778
6. N.S. Key, L.M. Aledort, D. Beardsley, H.A. Cooper, G. Davignon, B.M. Ewenstein Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors Thromb Haemost 80 1998 912 918
7. J. Ingerslev, H. Thykjaer, O. Kudsk-Jensen, U. Fredberg Home treatment with recombinant activated factor VII Results from one centre Blood Coagul Fibrinolysis 9 suppl 1 1998 S107 S110
8. V. Proulle, B. Hugel, B. Guillet, C. Trichet, A. Rafowicz, T. Lambert Injection of recombinant activated factor VII can induce transient increase in circulating procoagulant microparticles Thromb Haemost 91 2004 873 878
9. M.E. Carr Jr., E.J. Martin, J.G. Kuhn, S.V. Seremetis Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion Thromb Haemost 89 2003 803 811
10. S. He, G.J. Ekman, U. Hedner The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia J Thromb Haemost 3 2005 272 279
11. E. Erhardtsen, P. Nony, M. Dechavanne, P. Ffrench, J.P. Boissel, U. Hedner The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0 Blood Coagul Fibrinolysis 9 1998 741 748
12. W.T. Sumner, D.M. Monroe, M. Hoffman Variability in platelet procoagulant activity in healthy volunteers Thromb Res 81 1996 533 543
13. S. Schulman, R. d'Oiron, U. Martinowitz, J. Pasi, M.E. Briquel, E. Mauser-Bunschoten Experiences with continuous infusion of recombinant activated factor VII Blood Coagul Fibrinolysis 9 1998 S97 S101
14. A. Villar, S. Aronis, M. Morfini, E. Santagostino, G. Auerswald, H.F. Thomsen Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A Haemophilia 10 2004 352 359
15. T. Abshire, G. Kenet Recombinant factor VIIa Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors J Thromb Haemost 2 2004 899 909
16. G. Kenet, A. Lubetsky, J. Luboshitz, U. Martinowitz A new approach to treatment of bleeding episodes in young hemophilia patients A single bolus megadose of recombinant activated factor VII (NovoSeven) J Thromb Haemost 1 2003 450 455
17. H.A. Cooper, C.P. Jones, E. Campion, H.R. Roberts, U. Hedner Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures Haemophilia 7 2001 517 522
18. G. Kenet, A. Lubetsky, J. Luboshitz, B. Ravid, I. Tamarin, U. Martinowitz High dose recombinant activated factor VII for treatment of patients with hemophilia and inhibitors Haemophilia 10 2004 53 66
19. R. Parameswaran, A.D. Shapiro, J.C. Gill, C.M. Kessler HTRS Registry Investigators Dose effect and efficacy of recombinant factor VIIa (rFVIIa) in the treatment of haemophilia patients with inhibitors Analysis from the Hemophilia and Thrombosis Research Society Registry Haemophilia 11 2005 100 106
20. K. Kavakli, M. Makris, B. Zulfikar, Z. Abrams, G. Kenet NovoSeven® Trial (F7HAEM-1510) rFVIIa (NovoSeven) for the treatment of mild/moderate joint bleeds in haemophilia patients with inhibitors a double-blind study of a single high dose versus standard multiple doses of rFVIIa 2005 Presented at the XXth Congress of the International Society on Thrombosis and Haemostasis, Sydney, Australia, August 6-12
21. T. Hayashi, I. Tanaka, M. Shima, K. Yoshida, K. Fukuda, Y. Sakurai Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor Haemophilia 10 2004 397 400
22. J. Schneiderman, D.J. Nugent, G. Young Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors Haemophilia 10 2004 347 351
23. U. Martinowitz, T. Livnat, A. Zivelin, J. Luboshitz, U. Seligsohn, G. Kenet Concomitant infusion of low doses of rFVIIa and FEIBA in severe hemophilia A patients with an inhibitor to factor VIII who are refractory to rFVIIa or FEIBA has an excellent hemostatic effect and synergistically enhances thrombin generation. 2005 Presented at the XXth Congress of the International Society on Thrombosis and Haemostasis, Sydney, Australia, August 6-12
24. M.E. Carr Jr, E.J. Martin Evolving techniques for monitoring clotting in plasma and whole blood samples Clin Lab 50 2004 539 549
25. Y. Dargaud, A. Lienhart, S. Meunier, O. Hequet, H. Chavanne, V. Chamouard Major surgery in a severe haemophilia A patient with high titre inhibitor Use of the thrombin generation test in the therapeutic decision Haemophilia 11 2005 552 558
26. B. Sorensen, J. Ingerslev Tailoring haemostatic treatment to patient requirements - An update on monitoring haemostatic response using thrombelastography Haemophilia 11 suppl 1 2005 1 6
27. A. Yoshioka, K. Nishio, M. Shima Thrombelastgram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII Haemostasis 26 suppl 1 1996 139 142
28. B. Sorensen, J. Ingerslev Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa J Thromb Haemost 2 2004 102 110
29. T.C. Abshire Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients Improved efficacy with higher dosing Semin Hematol 41 suppl 1 2004 3 7